Deutsche Bank Ag\ Caribou Biosciences, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 49,576 shares of CRBU stock, worth $100,143. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,576

Previous 29,979 65.37%

Holding current value

$100,143

Previous $49,000 95.92%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.56 - $2.73 $30,571 - $53,499	19,597 Added 65.37%	49,576 $96,000
Q2 2024 Aug 14, 2024	SELL	$1.62 - $5.05 $9,222 - $28,749	-5,693 Reduced 15.96%	29,979 $49,000
Q1 2024 May 15, 2024	BUY	$4.82 - $8.26 $3,783 - $6,484	785 Added 2.25%	35,672 $183,000
Q4 2023 Feb 14, 2024	BUY	$3.58 - $6.25 $19,607 - $34,231	5,477 Added 18.62%	34,887 $199,000
Q3 2023 Nov 09, 2023	BUY	$4.08 - $8.14 $26,079 - $52,030	6,392 Added 27.77%	29,410 $140,000
Q2 2023 Aug 14, 2023	SELL	$4.04 - $5.47 $47,797 - $64,715	-11,831 Reduced 33.95%	23,018 $97,000
Q1 2023 May 15, 2023	BUY	$4.3 - $7.78 $42,200 - $76,352	9,814 Added 39.2%	34,849 $185,000
Q4 2022 Feb 13, 2023	BUY	$5.57 - $11.01 $16,804 - $33,217	3,017 Added 13.7%	25,035 $157,000
Q3 2022 Nov 14, 2022	SELL	$5.34 - $12.79 $4,918 - $11,779	-921 Reduced 4.01%	22,018 $232,000
Q2 2022 Aug 11, 2022	SELL	$5.1 - $9.74 $21,353 - $40,781	-4,187 Reduced 15.44%	22,939 $125,000
Q1 2022 May 13, 2022	BUY	$8.42 - $15.32 $118,823 - $216,195	14,112 Added 108.44%	27,126 $249,000
Q4 2021 Feb 11, 2022	BUY	$14.59 - $23.26 $18,908 - $30,144	1,296 Added 11.06%	13,014 $196,000
Q3 2021 Nov 04, 2021	BUY	$15.75 - $30.29 $184,558 - $354,938	11,718 New	11,718 $279,000

Others Institutions Holding CRBU

# of Institutions

135

Shares Held

52.6M

Call Options Held

148K

Put Options Held

70.7K

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $123M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account